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This letter describes an efficient approach by integrating virtual screening with 1 
bioassay technology for finding small organic inhibitors targeting β-secretase 2 
(BACE-1). 15 hits with inhibitory potencies ranging from 2.8 to 118 μM (IC50) 3 
against β-secretase were successfully identified. Compound 12 with IC50 of 2.8 μM is 4 
the most potent hit against BACE-1. Docking simulation from GOLD 3.0 suggests 5 
putative binding mode of 12 in BACE-1 and potential key pharmacophore groups for 6 
further designing of non-peptide compounds as more powerful inhibitors against 7 
BACE-1.  8 
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Alzheimer’s disease (AD), a neurodegenerative disorder, is the most common form 1 
of dementia and accounts for two thirds of all cases. The disease is getting worse and 2 
worse as the population of aging people is getting higher worldwide. Today it is the 3 
sixth-leading cause of death in the United States and has become a major social and 4 
economic burden for both the society and family
1
. Cure for this disease is currently 5 
unavailable although extensive research has been focused on the development of 6 
therapeutic approaches. Thus, investigations on new drug discovery and development 7 
for AD are of urgent necessity. AD is pathologically characterized by the presence of 8 
intracellular neurofibrillary tangles and extracellular senile plaques in the brain
2-4
. The 9 
major components of the plaques remained unknown until a small peptide termed beta 10 
amyloid (Aβ) was purified from neuritic plaques
5
. This peptide consists of 39-43 11 
residues that are endo-proteolytically derived from a transmembrane amyloid 12 
precursor glycoprotein (APP)
6
. Following the discovery and report of Aβ, a dominant 13 
hallmark of pathogenesis known as amyloid cascade hypothesis was developed to 14 
propose that the overproduction and aggregation of a 42-amino acid form of Aβ is 15 
followed by its deposition in the plaques in the brain
7-9
.  The endoproteolytic 16 
cleavage of the APP to get Aβ involves the sequential actions of two proteases, the 17 
β-secretase (BACE-1, hereinafter) and γ-secretase
10
. Therefore, BACE-1 has become 18 
an attractive therapeutic target and its inhibitors are potential drug candidates for the 19 
treatment of AD. In the past decade, the major effort in designing BACE-1 inhibitors 20 
was the production of transition state isosteres such as hydroxyethylamines, reduced 21 
amides, statine-based peptidometic inhibitors countering the catalytic aspartyl groups. 22 
 4 
However, no non-peptidic inhibitors were reported and none of the already reported 1 
BACE-1 inhibitors has been marketed as efficient drug so far due to the complication 2 
by the requirement for central nervous system penetration
11, 12
. Hence, identification 3 
of novel small non-peptide inhibitors is necessary to make the pharmacokinetic 4 
properties of chemicals more favorable for further development and enlarge the space 5 
of drug lead discovery as well as to bring the leads into pre-clinical and clinical trials. 6 
While peptidomimetic transition state isostere based inhibitors, such as statine, 7 
homostatine, norstatine, and hydroxyethylamine, have dominated the major effort in 8 
the design of potent inhibitors of human BACE-1. Li’s group employed a 9 
combinatorial chemistry approach to develop homostatine based inhibitor which had 10 
an IC50 value of 143 nM in an enzymatic assay
13
 and Shering-Plough Corp presented 11 
a hydroxyethylamine based inhibitor with an IC50 of 4 nM
14
. Only till recently, some 12 
non-peptide compounds were identified as inhibitors of BACE-1. Astex researchers 13 
highlighted their work in discovering aminopyridine and cyclic amidine classes as 14 
BACE-1 inhibitors
15
. Barrow et al reported the identification of spiropiperidine 15 
inhibitor template for BACE-1
16
. Although the inhibitors from others have been 16 
demonstrated potent in enzymatic assays, this has not discouraged us from exploring 17 
new BACE-1 inhibitors with alternative structural scaffolds. These inhibitors seldom 18 
enter the brain due to their unfavorable physicochemical properties, such as their high 19 
polar surface areas and high number of H-bond donors and acceptors as they are 20 
peptides in nature. Therefore, identifying selective nonpeptidic BACE-1 inhibitors 21 
 5 
with ideal hydrophobicity for CNS penetration and good pharmacokinetic properties 1 
would be demanding.  2 
To discover novel small molecule inhibitors with new chemical skeleton as 3 
potential drug leads, we applied a receptor-based virtual screening approach to 4 
search the compound database Specs (www.specs.net) containing ~280,000 5 
chemicals and identified 42 hit compounds. All calculations were performed on IBM 6 
cluster equipped with 64 processors. Crystal structure of BACE-1 complexed with 7 
an inhibitor OM00-3 (PDB entry: 1M4H) resolved at 2.1Å
17
 was extracted from 8 
Brookhaven Protein Data Bank (PDB) (www.rcsb.org/pdb). Hydrogen atoms were 9 
added and water molecules co-crystallized with the protein were removed from the 10 
original structure using Sybyl 8.0 (Tripos associate inc., St. Louis, MO, USA). The 11 
modified crystal structure of BACE-1 was used as the target for virtual screening on 12 
commercial chemical databases Specs by using GOLD 3.0 software (CCDC, 13 
Cambridge, U.K.). Chemical database Specs was edited from its original sdf file 14 
format to mol2 format. The default parameters in GOLD 3.0 were used. The active 15 
site radius is 15Ǻ from atom 1846 OD2 of Asp228, which is one of the key amino 16 
acid residues in the aspartyl protease. The GoldScore fitness function was applied 17 
and top 3000 molecules with the highest GOLDscores from initial virtual screening 18 
were then re-submitted for multiple docking of 10 conformations for each ligand. 19 
Finally, the top 1000 hits were selected for further visual inspection of their binding 20 
conformation and geometrical matching quality with the active sites of BACE-1. 21 
Based on the predicted putative H-bonds formed by the hits and active site residues 22 
 6 
of BACE-1, the potential hydrophobic and aromatic-aromatic interactions, as well as 1 
predicted clogP values of 4~6 for blood brain barrier, 42 compounds among the top 2 
1000 hits were selected for biological assays. Among them, 15 new potential 3 
BACE-1 inhibitors (Shown in Table 1) were discovered to be active through 4 
bioassay with FRET technology
18
, demonstrating that the applied approach is a 5 
highly efficient way to discover active compounds with new scaffold different from 6 
current peptidic BACE-1 inhibitors. In this study, nearly one-third of the compounds 7 
(12/42) demonstrated their inhibitory potencies of greater than 50% of BACE-1 at 8 
100 μM and the most active compound 12 identified from this work has an IC50 9 
value of 2.8 μM. Although it is weaker than the positive control, a statine-based 10 
peptide with an IC50 value of 120 nM from our test (reference IC50 value is 30 nM)
 19
, 11 
it is novel in terms of its organic structure with smaller molecular weight that makes 12 
it possible to penetrate the brain barrier. The generation of several different structural 13 
scaffolds as novel pharmacophores of BACE-1 inhibitors implies the possibility and 14 
importance of the fast, economic computer-assisted approach in modern drug 15 
discovery and design.  16 
From our docking study, all 15 inhibitors were proposed to bind with BACE-1 17 
within the enzyme active pocket. Due to the fact that BACE-1 consists of more 18 
sub-pockets (S4’-S4) than other aspartyl proteases in its active site, it is expected that 19 
inhibitors capable of interacting with more sub-sites could lead to stronger inhibitory 20 
effect. Such expectation is consistent with our bioassay results, as exemplified by 21 
inhibitory differences among all inhibitors. Compounds 12 and 13 with higher activity 22 
 7 
almost occupy the whole active pocket of BACE-1 while all the rest bind with 1 
BACE-1 mainly via S3-S3’ interaction. Notably, 12 exhibited low micromolar 2 
potency against BACE-1 in the FRET assay. As shown in Figure 1, molecular docking 3 
derived from GOLD suggested a reasonable binding mode of compound 12 in 4 
BACE-1. Being the central “bridge” of 12, the benzothiazole ring occupies S1 5 
sub-pocket, making aromatic-aromatic interaction with Tyr71. The linker sulfur group 6 
fits the small, shallow S3 and S4 pocket is occupied by di-methoxy phenyl group, 7 
contributing to hydrophobic and Van der Waals force within the site. The right (prime) 8 
side of the active site is mainly occupied by thiazine together with two piperidine 9 
groups on it. Several hydrogen bond interactions were observed from the docking 10 
simulation (Figure 2). Among them the most important interaction is the H-bond 11 
formed between the linker NH with oxygen in Asp228, thereby mimicking the isostere 12 
warheads in previously reported synthetically optimized inhibitors. Besides, Gly34 13 
and Tyr198 also form two hydrogen bonds with the triazine and piperidine in 12 14 
respectively. Interestingly, a similar molecule 13 with IC50 of 10.2 μM was also 15 
identified from the virtual screening. However, the change from dimethoxyphenyl 16 
group to fluorobenzne in 13 rendered the activity lose by 5 folds. Hence, the Van der 17 
Waals interactions between the Ala231 to the methoxy group on the P4 phenyl ring in 18 
the inhibitors might be essential for strong inhibition of the enzymatic activity. As 19 
little is known about the use of compound 12 elsewhere before, the chemical scaffold 20 
in 12 might represent a new class for further drug lead optimization targeting 21 
BACE-1.  22 
 8 
   Albeit compound 12 is a novel moderate inhibitor of BACE-1, further search of 1 
compounds bearing important pharmacophores in 12 will be continued. Furthermore, 2 
implementation of multiple scoring functions in preliminary computational 3 
predictions of potential hits would contribute to better enrichment rates during virtual 4 
screening and molecular docking process. Recently, Vijayan et al reported a hybrid 5 
structure-based virtual screening for identification of several prospective BACE-1 6 
inhibitors and the study ensured the superiority of the modified methodology over 7 
conventional docking methods in yielding higher enrichment rates
20
. 8 
   In summary, structure-based virtual screening in combination with bioassay 9 
resulted in identification of multiple novel non-peptide inhibitors of human BACE-1. 10 
This method provided an efficient and high hit-rate approach for inhibitor discovery 11 
against BACE-1. The inhibitors reported herein are mostly hydrophobic in nature with 12 
moderate molecular sizes (~500-600 Da). Therefore, they are possibly developed to 13 
be penetrants of blood brain barrier and able to achieve the terminal effect of 14 
addressing the underlying neuropathology. The most potent molecule, compound 12 15 
has a benzothiazole ring which docks into the S1 pocket of the enzyme and spans the 16 
interaction through almost all the sub-sites of BACE-1. The docking pose of 17 
compound 12 in the active site of BACE-1 is useful in guiding lead optimization and 18 
structure-activity relationships study in future. Encouraged by current knowledge, our 19 
effort in optimizing present sub-micromolar hits into more potent nanomolar leads 20 
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Table 1. Inhibition of β-secretase by compounds selected from virtual screening 2 
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100 0.12(+ 0.012) 
 1 
a
IC50 values are means of two experiments. S.D. values are given in parentheses. 
b 
IC50 values of 2 
compound 1, 3, 6, and 8 were estimated. 
c
The positive control in the assay demonstrated an IC50 value 3 
of 120 (+ 1.2) nM. 4 
5 
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Figure Legends 1 
Figure 1. Molecular docking derived binding pose of compound 12 in the active site 2 
(surface representation) of BACE-1. Inhibitor is colored by atom type. Two residues, 3 
Thr 72 and Gln 73, were deleted for a whole view of active site. Surfaces of catalytic 4 
aspartic acids 32 and 228 are colored in red. S4-S4’ sub-sites of BACE-1 are labeled 5 
in black. The binding mode was derived from GOLD and the picture was generated 6 
by InsightII software (Accelrys). 7 
 8 
Figure 2. A representation of docking simulated binding mode of compound 12 bound 9 
in the active site of BACE-1. Hydrogen bonds are represented by dotted lines. This 10 
figure was generated by ChemDraw 8.0. BACE-1 sub-pockets are labeled in “S” and 11 
corresponding chemical moieties in 12 are labeled in “P”. 12 
